2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
02:00 p.m. - 03:30 p.m.
MCCNO - New Orleans Theatre C
Technology and Procedures, Molecular Testing, Treatment Considerations, Supportive Care, Biological Therapies, Vaccines, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, ALL, CLL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, Translational Research, Clinical Research, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Survivorship, Study Population, Human, Adult
PAPER

314 Cytopenias and infections following CD20xCD3 bispecific antibodies (BsAbs) in relapsed/refractory (R/R) B-cell non-Hodgkin lymphoma (B-NHL): A multicenter real-world analysis

Fnu Amisha, MD, Ghada Araji, MD2, Rida Darji, MD3, Corbin Wright4, Syeda Saba Kareem, PharmD5, Biwei Cao6, Veronika Bachanova, MD, PhD7, Celeste Bello, MD8, Nima Ghalehsari, MD9, Supriya Gupta, MD10, Leidy Isenalumhe, MD, MS11, Michael D. Jain, MD, PhD12, Aleksandr Lazaryan, MD MPH PhD13, Frederick L. Locke, MD14, Sayeef Mirza, BS, MPH, MD15, Samuel Benjamin Reynolds, MD16, Lubomir Sokol, MD, PhD17, Bijal Shah, MD, MS18, Supreet Kaur, MD19, Javier Pinilla-Ibarz, MD PhD20, Yumeng Zhang, MD21, Madiha Iqbal, MBBS, MD22, Julio Chavez, MD23, Sameh Gaballa, MD24
1 University of Minnesota, Minneapolis, Minnesota, United States
2 H. Lee Moffitt Cancer Center, Tampa, United States
3 H. Lee Moffitt Cancer Center, Tampa, United States
4 H. Lee Moffitt Cancer center, Tampa, United States
5 H. Lee Moffitt Cancer Center, Tampa, United States
6 H. Lee Moffitt Cancer Center, Tampa, United States
7 University of Minnesota, Minneapolis, Minnesota, United States
8 H. Lee Moffitt Cancer Center, Tampa, United States
9 H. Lee Moffitt Cancer Center, Tampa, United States
10 University of Minnesota, Minneapolis, Minnesota, United States
11 H. Lee Moffitt Cancer Center, Tampa, United States
12 H. Lee Moffitt Cancer Center, Tampa, United States
13 H. Lee Moffitt Cancer Center, Tampa, United States
14 H. Lee Moffitt Cancer Center, Tampa, United States
15 H. Lee Moffitt Cancer Center, Tampa, United States
16 H. Lee Moffitt Cancer Center, Tampa, United States
17 H. Lee Moffitt Cancer Center, Tampa, United States
18 H. Lee Moffitt Cancer Center, Tampa, United States
19 H. Lee Moffitt Cancer Center, Tampa, United States
20 H. Lee Moffitt Cancer Center, Tampa, United States
21 H. Lee Moffitt Cancer Center, Tampa, United States
22 Mayo clinic Jacksonville, Jacksonville, United States
23 Mayo clinic Jacksonville, Jacksonville, United States
24 H. Lee Moffitt Cancer Center, Tampa, United States

Background: Glofitamab (Glofi), epcoritamab (Epco), and mosunetuzumab (Mosun) are FDA-approved BsAbs for R/R B-NHL. In pivotal trials, grade (G) ≥3 neutropenia occurred in ~25–40% and G≥3 infections in ~10–25%, with fatal infections up to ~5% (largely COVID-19). Real-world data on the post-pandemic incidence, timing, and risk factors of these toxicities remain limited.

Methods: We retrospectively reviewed adult patients (pts) with R/R B-NHL who received ≥1 dose of standard-of-care Glofi, Epco, or Mosun (Dec 2022- Jan 2026), followed to last contact or death. Serial labs were collected at baseline (Day [D] −14 to 0) and across 5 intervals (D1–30, D31–90, D91–180, D181–270, D271–365) up to 1 year [y]. Cytopenias and infections were graded per CTCAE v6.0. Death was treated as a competing risk for Cumulative Incidence. Fine-Gray univariable (UVA) and multivariable (MVA) models with sensitivity analyses, identified factors for all-grade and severe (G≥2) infection and neutropenia.

Results: Of 151 BsAb-treated pts (Glofi 68, Epco 53, Mosun 30), 124 as monotherapy and 27 in combination; 23% had bridging intent (30 to CAR-T, 5 to alloHCT). At BsAb start, median age 70y; 62% male; histology aggressive in 85% (de novo DLBCL 54, transformed DLBCL 35, high-grade 32, mantle 7) and indolent in 15% (all follicular); 83% stage IV, 30% ECOG ≥2, 52% ≥2 extranodal sites, 42% bulky >5 cm, 14% marrow and 9% CNS involvement; ferritin >2000 in 26% (of 96 evaluable) and CAR-HEMATOTOX >2 in 55% (of 69 evaluable). Pts were heavily pretreated: 54% ≥3 prior therapy, 41% prior CAR-T (66% axi-cel) and 34% prior bendamustine (78% follicular, <12 mo: 13pts, >12 mo: 24pts).

CRS incidence was 43% (14% G≥2) and ICANS was 12% (7% G≥2). Severe (G≥2) cytopenias were common at baseline and D1-30 (neutropenia 14% and 25%, anemia 48% and 25%, thrombocytopenia 19% and 18%, lymphopenia 67% [of 60 evaluable] and 92%). By D271–365, only G≥2 neutropenia (25%) and lymphopenia (68%) persisted. Despite their frequency, cytopenias rarely required intervention (D1–30: G-CSF 5%, RBC transfusion 5%, platelet transfusion 2%).

Overall, 56 pts (37%) had ≥1 infection and 48 (32%) a G≥2 infection (incidence density 7.25/100 pt-mo); 13% had ≥2 episodes (83 total). Per episode, 40% were G3, 5% G4, 5% G5 (fatal); 53% bacterial, 41% viral, 7% fungal, with fungal infections occurring earliest (median day 11), followed by bacterial (median day 43) and viral (median day 63). Infections were most often respiratory (upper 37%, lower 24%), gastrointestinal (13%), genitourinary (8%). Common pathogens were rhinovirus, parainfluenza, COVID-19, VZV, and C. difficile. Cumulative incidence of severe infection increased from 19% (D30) to 31% (D180) to 33% (D365) (any infection 23%/36%/39%). Antiviral and anti-PCP prophylaxis (ppx) was common (70–95% throughout), whereas antibacterial and antifungal ppx were uncommon (<5%), IVIG ppx increased from 5% (D1–30) to 38% (D271–365).

On UVA, all-grade infection risk increased with G≥2 CRS (HR 2.23; P=0.02); prior CAR-T (HR 1.77; P=0.03), baseline ferritin >2000 (HR 3.05, P=0.002), CAR-HEMATOTOX >2 (HR 2.61; P=0.03), and severe (G≥2) infection risk increased with G≥2 CRS (HR 2.34; P=0.01) and baseline ferritin >2000 (HR 4.61; P<0.001). On MVA adjusting for CRS, CAR-T, and ferritin (with multiple imputation for missing ferritin), G≥2 CRS independently predicted all-grade infection (aHR 2.04; P=0.04) and baseline ferritin >2000 independently predicted severe infection (aHR 2.46; P=0.009); findings consistent in complete-case and time-varying (cause-specific Cox). On UVA, severe neutropenia risk increased with marrow involvement (HR 3.52; P=0.005) and decreased with ≥6 mo from last therapy (HR 0.21; P=0.03), but none on MVA.

Median follow-up from BsAb start was 13.2 months (95% CI 11.3–17.8). BsAb was discontinued in 128 (85%)—most for progression (38%) or bridging (16%) or toxicity 14% (CRS 2, ICANS 2, infection 2), ); 23 (15%) ongoing. 59 (39%) died, most from lymphoma (59%). Non-relapse mortality (NRM) in 24 (16%), with 9 toxicity-related deaths (infection 7, CRS 2).

Conclusions: In R/R B-NHL treated with CD20×CD3 BsAbs, severe cytopenias—particularly lymphopenia and neutropenia—and infections are common, arise early (especially fungal and bacterial), and persist through the first year. Infections contribute significantly to NRM with CRS severity and inflammatory biomarkers identifying pts at highest risk, supporting risk-adapted monitoring and prophylaxis.

Fnu Amisha, MD: No relevant conflicts of interest to declare.